Etoricoxib and naproxen effective for arthritis

	Tweet

The COX-2 inhibitor etoricoxib and the older agent naproxen are both safe and effective for the treatment of arthritis, according to a report in the Annals of the Rheumatic Diseases.

Dr. Sean P. Curtis, of Merck Research Laboratories, Rahway, New Jersey, and colleagues studied etoricoxib at 60 milligrams once-daily versus naproxen 500 milligrams twice-daily over a 138-week period in patients with arthritis at 80 clinical centers in 19 countries. Nearly 1,000 patients were included in the study.

Etoricoxib and naproxen were comparable in their ability to reduce pain throughout the entire study period, the report indicates.

Both treatments were generally well tolerated and the side effects seen with each were similar. Still, more naproxen-treated patients were likely to discontinue the drug due to side effects than patients in the etoricoxib group.

“Regardless of treatment group, the most common (side effects) in the three study periods overall were upper respiratory infection and (High Blood Pressure),” they report.

The investigators also note that the study was not designed to compare the risk of gastrointestinal or heart side effects with each drug.

SOURCE: Annals of the Rheumatic Diseases, July 2007.

RELATED STORIES:
Arthritis pills little use in beating pain -study   Statins may cut pneumonia deaths: study   Many don’t disclose foregoing drugs   J&J changes heart drug label to show mortality risk   New Study Links Inflammation to Plaque Buildup In the Arteries of People with Rheumatoid Arthritis   Public to view drug side effects   A Treatment for Osteoarthritis in the Knees?   New way of classifying rheumatoid arthritis aimed at identifying the disease earlier   More research needed on painkiller safety   Scientists find more potent anti-TB drugs   Statins may cut stroke disability, deaths   “Miracle” Cancer Drug Gleevec Can be Toxic to the Heart

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]